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Introduction: Alzheimer’s disease (AD) neuropathological subtypes (limbic predomi-
nant [lpAD], hippocampal sparing [HpSpAD], and typical [tAD]), definedby relativeneu-
rofibrillary tangle (NFT) burden in limbic and cortical regions, have not been studied
in prospectively characterized epidemiological cohorts with robust cognitive assess-
ments.
Methods: Two hundred ninety-two participants with neuropathologically confirmed
AD from the Religious Orders Study andMemory and Aging Project were categorized
by neuropathological subtype based on previously specified diagnostic criteria using
quantitative regional NFT counts. Rates of cognitive decline were compared across
subtypesusing linearmixed-effectsmodels that included subtype, time, anda subtype–
time interaction as predictors and four cognitive domain factor scores (memory,
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executive function, language, visuospatial) and a global score as outcomes. To assess
if memory was relatively preserved in HpSpAD, non-memory factor scores were
included as covariates in themixed-effects model withmemory as the outcome.
Results: There were 57 (20%) with lpAD, 22 (8%) with HpSpAD and 213 (73%) with
tAD. LpAD died significantly later than the participants with tAD (2.4 years, P = .01)
and with HpSpAD (3.8 years, P = .03). Compared to tAD, HpSpAD, but not lpAD, per-
formed significantlyworse in all cognitive domains at the time of initial impairment and
declined significantly faster in memory, language, and globally. HpSpAD did not have
relatively preservedmemory performance at any time point.
Conclusion: The relative frequencies of AD neuropathological subtypes in an epidemi-
ological samplewere consistentwith aprevious report in a convenience sample. People
with HpSpAD decline rapidly, but may not have a memory-sparing clinical syndrome.
Cohort-specific differences in regional tau burden and comorbid neuropathology may
explain the lack of clinicopathological correlation.
KEYWORDS
Alzheimer’s disease, cognitive decline, cognitive trajectories, executive function, hippocampal
sparing, language, limbic predominant, memory, Memory and Aging Project, neuropathological
subtypes, Religious Orders Study, visuospatial function
1 INTRODUCTION
Alzheimer’s disease (AD) neuropathology is defined by the presence of
extracellular amyloid beta (Aβ) plaques and intraneuronal neurofibril-
lary tangles (NFTs) composed of hyperphosphorylated paired helical
filament tau (PHFtau) protein. In AD, the progressive neurofibrillary
degeneration of limbic and cortical brain regions has been tradition-
ally described by Braak staging,1,2 where there is substantial involve-
ment of the limbic structures, including the entorhinal cortex and
hippocampus, prior to cortical involvement. More recently, it has been
recognized that a subset of AD cases do not follow traditional Braak
staging, instead demonstrating disproportionate involvement of the
cortex with more limited involvement of the hippocampus.3–6 Murray
et al. formalized this distinction, describing three AD neuropatholog-
ical subtypes based on the absolute and relative NFT burden in lim-
bic and cortical brain regions: typical AD (tAD), limbic predominant
AD (lpAD), and hippocampal-sparing AD (HpSpAD).7 They found that
HpSpAD had a younger age at onset, declined faster, and died younger,
compared to tADand lpAD.Compared to tADand lpAD,HpSpADmore
often had ante mortem clinical diagnoses usually associated with non-
AD pathologies, including behavioral variant frontotemporal demen-
tia, progressive non-fluent aphasia, semantic dementia, progressive
supranuclear palsy, and Parkinson’s disease dementia. Further, they
estimated that HpSpAD and lpAD account for nearly 25% of neu-
ropathologically confirmed AD cases.
In addition to neuropathological subtypes, atypical clinical subtypes
of AD have also been described, including logopenic primary progres-
sive aphasia (PPA), posterior cortical atrophy (PCA), corticobasal syn-
drome (CBS), and a dysexecutive/frontal variant.8–11 These atypical
clinical subtypes are defined based on differences in cognitive profiles
compared to tAD and by definition demonstrate relatively preserved
memory compared to other cognitive domains. Even among patients
with tAD, there is marked variation in relative cognitive performance
in non-memory domains compared to memory performance, although
to a lesser extent than in atypical clinical AD phenotypes.12 Further,
there is longstanding clinicopathological and imaging evidence link-
ing episodicmemory to the hippocampus and related structures.5,13–16
Despite this indirect evidence, there has been limited research directly
linking AD neuropathological subtypes to neuropsychological trajec-
tories. The Murray et al. study was based on analyses from a con-
venience sample biorepository with limited prospective clinical data
(i.e., Mini-Mental State Examination [MMSE]; Clinical Dementia Rat-
ing [CDR]) and no uniform neuropsychological data.7 Petersen et al.
investigated cross-sectional neuropsychological performance near the
timeof death in ahighly selected sample classified intoADneuropatho-
logical subtypes.17 Further, because these studies were based on con-
venience samples, it is unclear if the observations generalize to the
larger population of older adults. Here, we use the prospective Reli-
gious Orders Study (ROS) and the community-based prospective Rush
Memory and Aging Project (MAP), both of which have robust longitu-
dinal, prospective cognitive data and large autopsy samples, to address
these questions. We used the Murray et al. criteria to identify tAD,
lpAD, and HpSpAD subtypes. We also used memory, language, visu-
ospatial, and executive function factor scores previously derived using
an advanced psychometric approach.18,19 We hypothesized that com-
pared to the tAD, HpSpADwould have faster cognitive decline, but rel-
atively bettermemory performance, and that lpADwould perform sim-
ilarly to tAD.
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2 METHODS
2.1 Participants
Participants were drawn from two different prospective clinicopatho-
logic cohorts of aging and dementia established at the Rush Univer-
sity Alzheimer’s Disease Center—ROS and MAP. ROS has enrolled
Catholic nuns, priests, and brothers nationally ages 65 or older since
1994.20–23 MAP has enrolled elderly individuals age 59 or older in
northeastern Illinois since 1997.23–25 Assessment procedures are the
same across studieswith a large common core of data, allowing the two
studies to be pooled across most data points.20,21,24 In both studies,
which together will be referred to as ROSMAP, participants agreed to
annual clinical assessment and cognitive testing, as well as brain dona-
tion. The autopsy rate is 86%, and participant follow-up exceeds 95%
annually.20 Detailed descriptions of ROSMAP can be found in previous
publications.20–26 Studies were approved by an Institutional Review
Board of Rush University Medical Center and all participants signed
documents indicating their informed consent, an Anatomical Gift Act,
and a repository consent to share tissue.
Included in the present study are ROSMAP brain donors examined
through October 2016 with pathological evidence of AD (i.e., National
Institute on Aging [NIA] Reagan intermediate or high) and Braak NFT
stage of V or VI, but without hippocampal sclerosis. The neuropatho-
logical inclusion criteria were chosen because they matched inclusion
criteria from Murray et al.7 Figure 1 shows an inclusion flowchart. Of
the 3149 total ROSMAP participants at the time of these analyses,
1595 had died, 898 had neuropathologically confirmed AD, and 292
met the neuropathological inclusion criteria and had non-missing data.
As shown in Figure 1, many of the people who had neuropathologically
confirmedAD, but were not included, had a Braak stage of IV or less, to
match theMurray et al. inclusion criteria.
2.2 Neuropathological evaluation
Assessment procedures were uniform and included a structured
assessment of common pathologies of aging. Brain tissue of deceased
ROSMAP participants were autopsied at Rush University and other
predetermined sites, and subsequently examinedbyneuropathologists
at Rush. Brains were analyzed according to standard protocols aligned
with accepted guidelines and reported previously.21,22,24,25,27 NFTs
were labeled with AT8, an antibody specific for PHFtau. Additionally,
NFTs were quantified using unbiased stereological mapping generat-
ing a continuous count (per mm2) in CA1/subiculum of the hippocam-
pus, midfrontal cortex, inferior temporal cortex, and the inferior pari-
etal lobule.28,29 Hippocampal sclerosis was determined to be present
or absent based on gliosis in CA1 and/or subiculum, and severe neu-
ronal loss in the region.30 Participantswith hippocampal sclerosiswere
excluded from these analyses to mirror Murray et al. criteria.7 See the
supporting information for additional details of the neuropathologic
examination.
HIGHLIGHTS
∙ Alzheimer’s disease (AD) neuropathological subtypes
were studied in epidemiological cohorts.
∙ Hippocampal-sparing AD (HpSpAD) performed worse in
all cognitive domains at initial impairment.
∙ HpSpAD declined faster in global cognition, memory, and
language.
∙ There is no evidence for relative sparing of memory per-
formance in HpSpAD.
RESEARCH INCONTEXT
1. Systematic review: A PubMed review showed that
Alzheimer’s disease (AD) neuropathological subtypes,
defined by regional neurofibrillary tangle burden, had
been examined in convenience samples with limited
prospective cognitive measures, but not in epidemiolog-
ical cohorts.
2. Interpretation: In two longitudinal clinicopathological
cohorts, therewere57 (20%)with limbic predominantAD
(lpAD), 22 (8%) with hippocampal-sparing AD (HpSpAD),
and 213 (73%) with typical AD (tAD). Compared to tAD,
HpSpAD, but not lpAD, performed worse in all cognitive
domains at the time of initial impairment and declined
faster in memory, language, and globally. HpSpAD did not
have relatively preserved memory performance. Cohort-
specific differences in regional tau burden and comorbid
neuropathology may explain the lack of clinicopathologi-
cal correlation.
3. Future directions: Development of cohort-independent
definitions of AD neuropathological subtypes and more
robust quantification of tau and other pathologies across
additional brain regions may allow for better harmoniza-
tion of clinical and neuropathological AD subtypes.
2.3 Derivation of neuropathological subtypes
Criteria for three neuropathological subtypes of AD (i.e., HpSpAD,
lpAD, and tAD) were adapted from Murray et al.7 with minor changes
due to differing study protocols as outlined below. To classify partic-
ipants, we considered the ratio of the hippocampal quantitative NFT
counts to that of the cortex to identify participants with relative spar-
ing of either region. In ROSMAP, NFT counts were based on AT8
immunostaining rather than thioflavin-S fluorescencemicroscopy used
byMurray et al.7 In ROSMAP, the subiculum andCA1 of the hippocam-
pus were considered together as a single region rather than being
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F IGURE 1 Inclusion/exclusion flowchart of participants.
Individual patient data from two prospective studies of aging
(Religious Orders Study and RushMemory and Aging Project) were
pooled. Inclusion/exclusion criteria were based onMurray et al.7
Curved arrows indicate excluded participants. Brain donors with
neuropathologically-confirmed Alzheimer’s disease (National
Institutes of Health-Reagan criteria) and Braak stage V or VI were
included. Donors with hippocampal sclerosis were excluded
considered separately and averaged. Four cortical regions with NFT
countswere considered in both studies: temporal cortex (superior tem-
poral region for Murray et al.; inferior temporal gyrus for ROSMAP),
inferior parietal lobule, middle frontal cortex, and the average of the
three regions.7
2.3.1 Hippocampal-sparing AD (HpSpAD)
Cases needed to meet the following three criteria: (1) The ratio of the
hippocampal NFT counts to the average cortical NFT counts had to be
less than the 25th percentile of all AD cases in the sample. (2) The hip-
pocampal NFT counts had to be less than themedian value. (3) At least
three of the cortical NFT count measures had to be greater than or
equal to themedian values.7
2.3.2 Limbic predominant AD (lpAD)
Cases needed to meet the following three criteria: (1) The ratio of the
hippocampal NFT counts to the average cortical NFT counts had to be
greater than the 75th percentile of all AD cases in the sample. (2) The
hippocampal NFT counts had to be greater than the median value. (3)
At least three of the cortical NFT counts measures had to be less than
or equal to themedian values.7
2.3.3 Typical AD (tAD)
These were cases that met criteria for AD, but did not meet neu-
ropathological criteria for either HpSpAD or lpAD.7
2.4 Clinical evaluation
Participants underwent yearly visits frombaseline until death to assess
cognitive status.20,21 The MMSE and a battery of tests of cognition31
were administered annually. Diagnoses of no cognitive impairment,
mild cognitive impairment (MCI), AD dementia, AD with other demen-
tias, and non-AD dementia were made annually using algorithmic
approaches shown to conform to standard approaches.32 A final diag-
nosis of the clinical status prior to death was determined based on a
review of all available data.
2.5 Derivation of cognitive scores
Descriptions of cognitive score derivations have been published.12,33
Briefly, among all participants with an AD dementia diagnosis, we used
granular (“item-level”) neuropsychological data from the first visit at
which a dementia diagnosiswasmade. Each trial administered to a par-
ticipant was deemed an “item.” A panel of experts including two neu-
ropsychologists and a behavioral neurologist (JM, ET, AJS) considered
each item individually anddesignated it as primarily ameasure ofmem-
ory, executive functioning, language, visuospatial functioning, or none
of these. We used modern psychometric methods to obtain scores for
each of the four cognitive domains. Modern psychometric approaches
have proven to have incrementally better validity data than scores
derived from standard approaches.12,18,19 We used Mplus 7.434 to fit
confirmatory factor analysis bifactor models for each domain sepa-
rately. We considered several approaches for specifying the bifactor
model for each domain (see the supplemental materials of our previ-
ous work33) and chose the model with the best model fit. All scores
were scaled to have a mean of 0 and a standard deviation (SD) of 1.
The parameter specifications used to derive the scores at the time of
dementia diagnosis were then used to obtain a factor score for each
cognitive domain for each participant at all visits. Table S1 in support-
ing information shows items assigned to and the secondary structure
for each cognitive domain.
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2.6 Statistical analyses
Unadjusted comparisons of demographic, clinical, and neuropatholog-
ical characteristics between neuropathological subtypes were con-
ducted using a Fisher’s exact test for nominal variables and analysis
of variance for continuous variables. When appropriate, post hoc tests
were performed using Scheffe’s method to control for multiple com-
parisons of continuous variables and Bonferroni correction for cate-
gorical variables.
We hypothesized that HpSpAD would demonstrate faster cogni-
tive decline and built models to determine the relative rate of cogni-
tive decline between subtypes. In five separate mixed-effects models
with random slopes and intercepts, we tested the association of neu-
ropathological subtype, time, and the subtype–time interaction with
each of the four cognitive scores and their average (termed global
cognition). In each model, tAD was considered the reference group.
Time= 0was specified as the time atwhich a diagnosis of any cognitive
impairment (MCI+; i.e., either MCI or dementia) was first made (e.g., a
visit 10 years prior toMCI+was assigned a time of –10; a visit 10 years
after MCI+ was assigned a time of +10). We chose this time schema
to affix time to a clinical diagnosis. For this time schema to work, we
excluded individuals who were never diagnosed with MCI+ (n = 13).
Additional covariates in the models included age at MCI+, sex, educa-
tion, and apolipoprotein E (APOE) genotype, defined as ≥ 1 ε4 alleles
versus 0 ε4 alleles. We did not consider race because nearly all partic-
ipants were White. In sensitivity analyses, we re-ran the models using
LOESS (locally estimated scatterplot smoothing) regression to visually
assess linearity because the rate of cognitive decline may not be con-
stant over time. In additional sensitivity analyses, we considered other
neuropathologicalmeasures (presenceof limbic/neocortical Lewybod-
ies, moderate or severe transactive response DNA-binding protein of
43 kDa [TDP-43], moderate or severe arteriolosclerosis, moderate or
severe atherosclerosis, moderate or severe cerebral amyloid angiopa-
thy [CAA], presence of gross infarcts, and presence ofmicroinfarcts) as
covariates in ourmixed effectsmodels to test whether the relationship
between AD subtype and cognitive trajectories were independent of
comorbid pathology.
Next, we hypothesized that that HpSpAD would have more pre-
served memory performance relative to other cognitive domains
compared to the other subtypes. We added the language, visu-
ospatial, and executive function scores as covariates in the mixed-
effects model with memory score as the outcome. This model
allowed us to generate a predicted “relative” memory score and
to test whether memory declined faster than the other domains
across subtypes. A positive predicted “relative” memory score repre-
sents better memory performance than would be expected based on
language, visuospatial, and executive function performance. Again, in
sensitivity analyses, we repeated the LOESS regression to assess for
linearity and considered the additional neuropathological measures
as covariates in the mixed effects model. All models were run in
Stata 16.35
3 RESULTS
Table 1 outlines the demographic and diagnostic characteristics of
the 292 included participants. Two hundred fifteen (74%) participants
were women, mean age at first visit was 81.3 years (SD = 5.8), mean
age at last visit was 88.3 years (SD = 5.8), and mean age at death was
89.9 years (SD = 5.6). The final diagnosis prior to death was demen-
tia for 211 (72%) participants, MCI for 54 (18%) participants, and
not cognitively impaired for 27 (9%) participants. The overall sample
included 125 (43%) peoplewith≥ 1APOE ε4 allele. Table S2 in support-
ing information shows demographic and clinical features of included
and excluded neuropathologically confirmed AD cases in ROSMAP.
Excluded participants were older at the time of MCI+ and dementia
diagnoses, were less clinically impaired, and more frequently did not
have an APOE ε4 allele. Table S3 in supporting information shows the
median, interquartile range (IQR), and range ofNFT counts across each
region byADneuropathologic subtype. It also shows the average corti-
cal counts and the ratio of hippocampal to average cortical.
tAD was identified in 213 (73%) participants, lpAD was identified
in 57 (20%) participants, and HpSpAD was identified in 22 (8%) par-
ticipants. Although the omnibus test identified significant sex differ-
ences by subtype, post hoc subtype comparisons were non-significant
after correction formultiple testing. Participantswith lpADdied signif-
icantly later than the participantswith tAD (2.4 years, P= .01) andwith
HpSpAD (3.8 years, P = .03). The frequency of clinical diagnosis (i.e.,
no cognitive impairment, MCI, AD dementia, AD with other demen-
tias, and non-AD dementia) at the last visit did not significantly differ
by subtype. There were no participants with HpSpADwith a final diag-
nosis of normal cognition, but that difference was not statistically dif-
ferent due to the small sample size (n = 22). The frequency of APOE ε4
allele carriers did not significantly differ by subtype.
Comorbid pathologies36,37 were common with 73 (25%) partici-
pantswith limbic/neocortical Lewy bodies, 120 (41%) participantswith
moderate to severe TDP-43, 103 (35%) participants with moderate
to severe arteriolosclerosis, 100 (34%) participants with moderate
to severe atherosclerosis, 169 (58%) participants with moderate to
severe CAA, 94 (32%) participants with gross infarcts, and 83 (28%)
participantswithmicroinfarcts. The frequency of these pathologies did
not significantly differ across subtypes (Table 2).
Meannumber of visitswas7.7 (SD4.1) for a total of 2235annual vis-
its. Table 3 shows mean MMSE, global cognition, and domain scores at
first and last visits, and at time of MCI, MCI+, and dementia diagnoses
across the three subtypes. In linear mixed-effects models adjusted for
age at death, sex, education, and APOE ε4 status, HpSpAD performed
significantly worse in global cognition, memory, visuospatial function,
executive function, and language compared to tAD at the time ofMCI+
diagnosis (Table 4). On average, performancewas 0.88, 1.22, 0.52, 0.57,
and 1.16 standardized units lower, respectively, forHpSpAD compared
with tAD at the time of MCI+ diagnosis. lpAD and tAD did not signif-
icantly differ in global cognition, memory, visuospatial function, exec-
utive function, or language at the time of MCI+ diagnosis. Overall,
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Female, n (%) 38 (67%) 12 (55%) 165 (77%) 215 (74%) .03e
Age, mean (SD)




























































Race, n (%) 1.0h
White 56 (98%) 22 (100%) 207 (97%) 285 (98%)
Black 1 (2%) 0 (0%) 5 (2%) 6 (2%)
Asian 0 (0%) 0 (0%) 1 (< 1%) 1 (< 1%)











First clinical diagnosis .047
No impairment 32 (56%) 7 (32%) 94 (44%) 133 (46%)
MCI 19 (33%) 6 (27%) 80 (38%) 105 (36%)
AD dementia 6 (11%) 7 (32%) 37 (17%) 50 (17%)
ADw/other dementia 0 (0%) 1 (5%) 1 (< 1%) 2 (1%)
Non-AD dementia 0 (0%) 1 (5%) 1 (< 1%) 2 (1%)
Last clinical diagnosis .49
No impairment 6 (11%) 0 (0%) 21 (10%) 27 (9%)
MCI 10 (18%) 6 (27%) 38 (18%) 54 (18%)
AD dementia 35 (61%) 13 (60%) 138 (65%) 186 (64%)
ADw/other dementia 5 (9%) 2 (9%) 14 (7%) 21 (7%)
Non-AD dementia 1 (2%) 1 (5%) 2 (1%) 4 (1%)
≥ 1 APOE ε4 allele 23 (40%) 13 (59%) 89 (42%) 125 (43%) .31
Abbreviations: AD, Alzheimer’s disease; APOE, apolipoprotein E;MCI, mild cognitive impairment;MMSE,Mini-Mental State Examination; SD, standard devi-
ation.
aParticipants whowent from cognitively normal to dementia, skippingMCI, are not included in themean age ofMCI onset.
bMCI+ refers to eitherMCI or dementia.
cLast visit was first visit for n= 18.
dAnalysis of variance or Fisher’s exact test.
ePost hoc pairwise tests were non-significant after correction for multiple testing.
fPost hoc pairwise tests were significant for the lpAD–tAD comparison.
gPost hoc pairwise tests were significant for the lpAD–tAD and lpAD–HpSpAD comparisons.
hWhite versus any other race.
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TABLE 2 Neuropathological features across subtypes, mean (SD) or n (%)
Characteristic Limbic predominant Hippocampal-sparing Typical Overall Pb











19 (33%) 5 (23%) 49 (23%) 73 (25%) .28
TDP-43a 19 (36%) 12 (67%) 89 (49%) 120 (48%) .23
Braak VI 0 (0%) 1 (5%) 13 (6%) 14 (5%) .15
Arteriolosclerosisa 23 (40%) 10 (45%) 70 (33%) 103 (35%) .33
Atherosclerosisa 20 (35%) 11 (50%) 69 (32%) 100 (34%) .27
CAAa 29 (51%) 16 (73%) 124 (58%) 169 (58%) .22
Gross infarcts 18 (32%) 9 (41%) 67 (31%) 94 (32%) .65
Microinfarcts 19 (33%) 7 (32%) 57 (27%) 83 (28%) .53
Abbreviations: CAA, cerebral amyloid angiopathy; SD, standard deviation; TDP-43, transactive response DNA-binding protein of 43 kDa.
aModerate or severe.
bAnalysis of variance or Fisher exact test.
participants significantly declined in every cognitive domain as well as
in global cognition over time (Figure 2). HpSpAD declined on average
0.11, 0.16, and 0.24 standardized units faster per year in global cogni-
tion, memory, and language, respectively, compared to tAD (Figure 2).
There were no significant differences between lpAD and tAD for rate
of decline in global cognition or any of the cognitive domains. Results
remained similar in sensitivity analyses adjusted for seven pathologi-
cal comorbidities (presence of limbic/neocortical Lewy bodies, moder-
ate or severe TDP-43,moderate or severe arteriolosclerosis, moderate
or severe atherosclerosis, moderate or severe CAA, presence of gross
infarcts, and presence of microinfarcts; data not shown). In sensitiv-
ity analyses using LOESS regression, models appeared linear by visual
assessment, and tests for three-way interactions among time, MCI+
status, and subtype were nonsignificant (data not shown).
The relative memory score is a measure of predicted memory per-
formance relative to the other cognitive domains. It is derived by
regressing the memory factor score on the other cognitive domain
factor scores (i.e., visuospatial, executive functioning, and language)
in a mixed effects model that also includes AD subtype, time, and
the subtype–time interaction. Across all participants, memory perfor-
mance declined significantly faster than would be predicted by the
decline in the other cognitive domains. On average, memory declined
0.05 standardizedunits faster per year thanpredictedby theother cog-
nitive domains. The relative memory score did not significantly differ
between subtypes at the time of MCI+ diagnosis, and rates of decline
of the relativememory score also did not differ between subtypes.
4 DISCUSSION
In a community-based sample of 292 deceased brain donors with AD
pathology from the ROS and MAP cohorts, the relative frequency of
AD neuropathological subtypes (HpSpAD, lpAD, tAD) was consistent
with aprevious report in a convenience sample,withHpSpADand lpAD
making up nearly 30% of neuropathologically confirmed AD cases.
Congruous with Murray et al.,7 HpSpAD, in comparison to lpAD and
tAD,was less frequent; had a younger age at death on average; and had
a higher male-to-female ratio, though this difference was nonsignifi-
cant after correction formultiple testing.Contrary toprevious findings,
subtype differences in comorbid neuropathologies and APOE ε4 alleles
were not identified.
This study also confirms and expands on previous studies that
assessed longitudinal performance of AD neuropathological subtypes.
Murray et al. showed that among 88 brain donors who had at least
twoMMSE scores, the difference between the first and last scores was
larger for HpSpAD compared to tAD and lpAD. These data were only
available in a small subset of the full study group inMurray et al.’s anal-
yses (n = 889) and there was not uniform neuropsychological assess-
ment to more comprehensively assess cognitive trajectories. Risacher
et al. grouped living amyloid-positive Alzheimer’s Disease Neuroimag-
ing Initiative participants into analogous subtypes based on baseline
hippocampal volume to cortical volume ratio measured on structural
magnetic resonance imaging.38 They found that among 100 partic-
ipants with 2-year longitudinal data, people with HpSpAD declined
faster than people with lpAD on the Alzheimer’s Disease Assessment
Scale, 13-ItemSubscale (ADAS-Cog13),MMSE, and Functional Assess-
ment Questionnaire and declined faster than tAD on the MMSE and
CDR Sum of Boxes. Memory and executive scores did not significantly
decline and neuropathology data were not available.33,38 The cur-
rent study expands on these studies by assessing cognitive domain–
specific trajectories over a mean of 8 years in a larger sample of par-
ticipants with neuropathologically defined AD subtypes. On average,
over time, the full cohort demonstrated significant declines inmemory,
visuospatial, executive functioning, and language domains, as well as in
global cognition. Compared to those having tAD, people with HpSpAD
declined faster in memory, language, and global cognition and were
more impaired at the time of MCI+ diagnosis in memory, language,
executive function, visuospatial, and global cognition. Average rates of
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TABLE 3 Cognitive scores across subtypes at various timepoints, mean (SD, range)
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TABLE 3 (Continued)




















































































Abbreviations: AD, Alzheimer’s disease;MCI, mild cognitive impairment;MMSE,Mini-Mental State Examination.
Notes: MCI+ refers to eitherMCI or dementia.
Participants who went from cognitively normal to dementia, skipping MCI, are not included in scores at MCI diagnosis, but they are included in scores for
MCI+ diagnosis.
aBased on analysis of variance.
bPost hoc pairwise tests were significant for the lpAD–HpSpAD comparisons.
cPost hoc pairwise tests were significant for the tAD–HpSpAD comparisons.
TABLE 4 Estimated cognitive scoresa and timeb (95% confidence interval), compared to typical AD, mixed effects modelsc,d





























































Abbreviations: AD, Alzheimer’s disease; APOE, apolipoprotein E;MCI, mild cognitive impairment.
aScores are in standard units.
bTime is years fromMCI+ diagnosis, with positive values occurring afterMCI+ diagnosis.
cAdjusted for age at death, sex, years of education, and presence of an APOE ε4 allele.
dN= 277 for thesemodels rather than 279 because APOE genotypewasmissing for two participants.
eDerived by adding visuospatial, executive functioning, and language scores as covariates to themodel withmemory score as the outcome.
decline for people with lpAD and people with tAD were similar across
cognitive domains and globally and these subtypes did not significantly
differ in any of the cognitive domains at the time ofMCI+ diagnosis.
We had hypothesized that HpSpAD would have preserved mem-
ory performance relative to other cognitive domains compared to the
other subtypes. We assessed this by regressing memory performance
on each of the other cognitive domain scores and using the predicted
“relative” memory score as a measure of how much better or worse
memory performance was relative to the other cognitive domains. On
average, across the cohort, memory declined faster than the other
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F IGURE 2 Predicted cognitive scores over time of Alzheimer’s disease neuropathological subtypes. Predicted scores were obtained from five
mixed-effects models with neuropathological subtype, time in years (with t= 0 at time of mild cognitive impairment [MCI+] diagnosis), and the
subtype–time interaction as predictors and the four cognitive scores (A-D) and their average (global cognition) (E) as outcomes; Typical
Alzheimer’s disease (tAD) was the reference group. Overall, participants significantly declined in each cognitive domain and globally over time.
Limbic predominant (lpAD) and tAD subtypes did not significantly differ at the time ofMCI+ diagnosis or in the rate of decline in each of the
cognitive domains or globally. Hippocampal-sparing AD (HpSpAD) was significantly more impaired at the time ofMCI+ diagnosis than tAD in
memory (A), executive function (B), visuospatial function (C), language (D), and globally (E). HpSpAD declined significantly faster than tAD in
memory (A), language (D), and globally (E), but not in executive function (B) or visuospatial function (C). An additional mixed-effects model (F)
added language, visuospatial, and executive function scores as covariates to themodel withmemory as the outcome (relative memorymodel).
Across all subtypes, memory performance declined significantly faster than would be predicted by the decline in the other domains. No significant
differences were observed in the relativememory score between subtypes at the time ofMCI+ diagnosis or over time
cognitive domains. Contrary to our hypothesis, across subtypes, the
relative memory score did not differ at the time of MCI+ diagno-
sis and the rate of decline of the relative memory score did not dif-
fer. Together, these results imply that, on average, over the course of
the study, there was not a time when participants with HpSpAD had
disproportionate sparing of memory performance relative to perfor-
mance in other domains. Our hypothesis was based on longstanding
clinicopathological and imaging evidence linking episodic memory to
the hippocampus.14,16,39 There is also substantial evidence showing
correlations between clinical subtypes of atypical AD and different
anatomic distributionsofPHFtaupathology in thebrainboth fromneu-
ropathological assessment and from taupositron emission tomography
scans.5,17,38–40 For instance, PHFtau pathology is disproportionately
found in inferior parietal and superior temporal cortices in logopenic
PPA and disproportionately found in the posterior parietal and occipi-
tal cortices in PCA.8 Compared to the current study, most of these past
studies were conducted in clinic-based samples composed of younger
individuals with atypical presentations at the phenotypic extremes. In
contrast, ROSMAP participants are older and sampled from the com-
munity.
Compared to these other studies, the older age of ROSMAP partic-
ipants may have had several implications. Both HpSpAD and atypical
clinical AD subtypes tend to have a younger age at onset than the other
corresponding neuropathological and clinical subtypes.41–43 Similarly,
NFT density in the neocortex and the NFT distribution in association
cortices relative to hippocampal structures tend to be greater among
peoplewho develop AD at younger ages.44 Consistently, in our sample,
compared toMurray et al., therewere fewer participantswithHpSpAD
(8% vs. 11%) and more with lpAD (20% vs. 14%). Additionally, because
the algorithm to derive neuropathological subtypes is a function of the
regional NFT counts median and IQR of the sample being studied, the
absolute and relative regional density required to meet criteria for a
given subtype may vary by study. Indeed, we observed markedly more
NFTs in the hippocampus compared to Murray et al., but counts in the
cortical regionswere similar across studies. The additional pathology in
the hippocampus may be responsible for memory not being relatively
URETSKY ET AL. 11 of 13
preserved in HpSpAD. This limitation of the criteria also complicates
cross-cohort comparisons and the generalizability of findings beyond
any given cohort studied.
The older age of ROSMAP compared to other studies of AD neu-
ropathological subtypes also likely led to higher proportions of comor-
bid pathology. It is possible that their high rates of comorbid pathol-
ogy confounded the regional effects of the PHFtau pathology on cog-
nitive performance. For instance, HpSpAD had a higher proportion
(albeit non-significant) of concomitant moderate to severe TDP-43
pathology (67%) compared to tAD (49%) and HpSpAD (36%). TDP-
43 pathology distributes around limbic regions and is associated with
memory impairment.45 Among participants with HpSpAD, those with
TDP-43 had more impaired memory (albeit non-significant) compared
to those without TDP-43 (Table S3). This may explain the promi-
nent memory deficits in the HpSpAD group. Similarly, lpAD had a
higher frequency (albeit non-significant) of comorbid Lewy body dis-
ease (LBD; 33%) compared to tAD (23%) and HpSpAD (23%). LBD is
associated with visuospatial and executive impairment46,47 and may
have similarly confounded group differences in cognition. Although
we did adjust for comorbid pathologies in our mixed effects mod-
els, the measures of comorbid pathologies were global rather than
regional.
An alternative explanation for the lack of clinicopathologic correla-
tion in the neuropathological subtypesmay relate to insufficient atten-
tion to regional cortical burden. Although the relative burden of PHF-
taupathology in thehippocampusversus the cortex is considered in the
definition, the distribution of pathology across the cortex is not con-
sidered. Including regional cortical burden in neuropathological sub-
typing may improve clinicopathological correlation with respect to rel-
ative cognitive domain performance. Indeed, the non-memory cogni-
tive domain most disproportionately affected in HpSpAD (language)
can be localized to two (inferior temporal, inferior parietal) of the
three cortical regions used in the algorithm to derive subtypes. Inter-
estingly, Petersen et al. recently proposed an alternative hierarchical
clustering approach to neuropathological AD subtyping and showed in
their clinic-based sample enriched for atypical subtypes, the alterna-
tive approach correlated better with clinical indicators than the Mur-
ray et al. approach.7,17 Both approaches only use three cortical regions;
sampling of more cortical regions may improve correlation with cogni-
tive performance.
Another explanation for the lack of clinicopathologic correlation
in the neuropathological subtypes may relate to the test items that
contribute to the cognitive factor score. Although these items were
assigned to the memory domain by expert clinicians and were sub-
sequently shown to better correlate with each other than with items
in other domains, the memory domain items nonetheless assess mul-
tiple types of memory, including verbal episodic encoding, retrieval,
and recognition. Considering these memory subtypes separately may
result inbetter clinicopathological correlation.A similar rationale could
bemade for subtypes of the other cognitive domains.
The study has several strengths. To our knowledge, this is the first
time cases of neuropathologically confirmed AD from a community-
based study were neuropathologically subtyped using rich quantita-
tivemeasures of PHFtau pathology acrossmultiple brain regions. Brain
donors were administered a full, prospective, neuropsychological bat-
tery, the items fromwhichwere used to derive psychometrically sound
domain-specific scores. A limitation of the study was the sample size,
at least relative to Murray et al., in which AD neuropathological sub-
types were first described. Although 1378 ROSMAP participants had
come to autopsy, only 292 met inclusion criteria as proposed in Mur-
ray et al. With the intent of replicating the subtyping procedures of
Murray et al., we limited inclusion to NIA Reagan intermediate or high
probability of AD, a Braak stage of V or VI, and no evidence of hip-
pocampal sclerosis. Although these inclusion/exclusion criteria were
necessary for replicating the Murray et al. approach, we nonetheless
excluded 67.5% of participants who met NIA Reagan criteria for AD
and 100% who had co-occurring AD and hippocampal sclerosis. Not
surprisingly, these excluded participants with lower Braak scores who
were less cognitively impaired. For improved generalizability, subtyp-
ing would not exclude these participants. Additionally, due to the sam-
ple size, we were unable to limit analyses to participants with incident
cognitive impairment. For instance, there were only seven participants
withHpSpADwith incident impairment. Differences in the frequencies
of incident and prevalent cases across subtypes may have contributed
to the consistently lower cognitive scores in HpSpAD, as well as other
observed differences. An additional limitation is the minor differences
in neuropathological assessment compared to Murray et al. By com-
bining CA1 and subiculum into a single region in our study, the crite-
ria for HpSpAD and LpAD became marginally more permissive. This
may explain the marginally smaller frequency of tAD seen in our study
compared to Murray et al (73% vs. 75%). Additionally, tau burden in
the subiculumhas beenmore clearly linkedwith an amnestic syndrome
than in CA117 and combining the regions may have diluted the mea-
sured relationships with memory function. The use of AT8 immunos-
taining compared to thioflavin-S in Murray et al. may have also intro-
duced differences in NFT tangle quantification. Thioflavin-S detects
mostly mature tangles and ghost tangles, while AT8 primarily detects
earlier NFT maturity levels.48 Additionally, ROSMAP does not code
diagnoses of atypical AD syndromes including logopenic PPA, PCA,
CBS, or a dysexecutive/frontal variant so we could not report the fre-
quencies of these diagnoses in the sample.
5 CONCLUSION
In this community-based study of neuropathologically confirmed cases
of AD, we identified similar frequencies of AD neuropathological sub-
types (lpAD, tAD, HpSpAD) as described previously in a large conve-
nience sample. People with HpSpAD declined faster across multiple
cognitive domains and globally than people with tAD or lpAD. How-
ever, no differences in relative memory performance were identified
across subtypes.Cohort-specific differences in regional tauburdenand
comorbid neuropathology may explain the lack of clinicopathological
correlation. Effectively defining and characterizing AD subtypes may
aid in prognosis, enrollment in clinical trials, and ultimately the devel-
opment of a personalizedmedicine approach to AD.
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